Can B Corp. FY22 Revenue Grows 45% To $6.7M, Here Are The Details
Can B Corp. FY22 Revenue Grows 45% To $6.7M, Here Are The Details
Can B Corp. (OTCQB:CANB) released its financial results for the twelve months ended December 31, 2022, revealing revenue increased 45% to $6.7 million, compared with $4.6 million in 2021.
Can B Corp. (OTCQB: CANB) 公布了截至2022年12月31日的十二个月的财务业绩，披露 收入增长了45％，达到670万美元， 相比之下，2021年的这一数字为460万美元。
Financial Highlights for 2022
2022 年财务亮点
-
Gross profit decreased 13% to $2.6 million.
-
Gross margin decreased to 39.1%, compared to 65.0% in 2021.
-
Adjusted EBITDA loss decreased by 25% to $2.1 million.
-
Net loss was $14.9 million, or ($4.18) per share, an increase of $2.8 million, or 23%, compared with a net loss of $12.1 million, or a net loss of ($9.06) per share, for the twelve months ended December 31, 2021. On a per-share basis this loss is a 46% reduction over 2021.
-
Total assets at $15.6 million.
-
毛利下降了13％，至260万美元。
-
毛利率下降至39.1％，而2021年为65.0％。
-
调整后的息税折旧摊销前利润亏损下降了25％，至210万美元。
-
净亏损为1,490万美元，合每股亏损4.18美元，增加了280万美元，增幅23％，而截至2021年12月31日的十二个月净亏损为1,210万美元，即每股净亏损9.06美元。按每股计算，亏损比2021年减少了46％。
-
总资产为1,560万美元。
Corporate Debt Restructuring to Position for Uplisting to National Securities Exchange
公司债务重组有望在国家证券交易所上市
Through the restructuring, Can B raised $1.55 million of new capital and extended previously due notes payable totaling $7.0 million to September 1, 2023, and December 31, 2024, to give the company an additional window to deploy the capital from the new raise. A key component of the restructuring was the sale of $5.7 million of accounts receivable from Can B's Duramed Inc. and Duramed MI, LLC divisions to fund payments on two promissory notes for $2.5 million and $1.5 million due to Can B Corp's largest institutional investor.
通过重组，Can B 筹集了155万美元的新资金，并将先前到期的总额为700万美元的应付票据延长至2023年9月1日和2024年12月31日，为公司提供了额外的窗口来部署新筹集的资金。重组的一个关键组成部分是出售Can B's的570万美元应收账款 Duramed Inc. 和 密歇根州杜拉梅， 有限责任公司 各部门将为两张期票的支付提供资金，分别为250万美元和150万美元应归于Can B Corp最大的机构投资者。
Marco Alfonsi, Can B's CEO, stated, "2022 was a transition year for us, for as we increased revenue as expected and achieved record annual revenue of $6.7 million, we had to deal with consolidating business and integrating our acquisitions. We are pleased with the position of our business heading into the remainder of 2023."
马可·阿方西，Can B 首席执行官表示：“2022 年对我们来说是过渡年，因为随着我们按预期增加收入并实现创纪录的670万美元年收入，我们不得不处理整合业务和整合收购的问题。我们对2023年剩余时间的业务状况感到满意。”
Alfonsi concluded, "While we generated an all-time high in annual revenue, we were able to also reduce our cash burn as demonstrated by the 25% decrease in adjusted EBITDA loss to $2.1 million. Our team made great strides over the past several months integrating and ramping up the various operations. We strategically acquired additional processing equipment to complete our vertical hemp processing capabilities from biomass to crude to distillate to isolate to isomers- all now located in our Colorado operation. We are executing on major strategic agreements, such as Pure Health Products' deal with Brooke Burke Superfood, and are very excited about the demand and results thus far. As we look forward in 2023, we are enthusiastic regarding the growth opportunities and prospects for our business and are in position for an uplisting to a national securities exchange."
阿方西总结说：“尽管我们的年收入创下了历史新高，但我们也能够减少现金消耗，调整后的息税折旧摊销前利润亏损减少了25％，至210万美元，就证明了这一点。在过去的几个月中，我们的团队在整合和加强各种业务方面取得了长足的进步。我们战略性地购买了额外的加工设备，以完善我们的垂直大麻加工能力，从生物质到原油再到馏出物再到分离物再到异构体，所有这些都位于我们的科罗拉多州工厂中。我们正在执行重大战略协议，例如 纯健康产品'处理 布鲁克·伯克超级食品，并对迄今为止的需求和结果感到非常兴奋。展望2023年，我们对业务的增长机会和前景充满热情，并准备在国家证券交易所上市。”
Photo by Esteban López on Unsplash
埃斯特万·洛佩兹在 Unsplash 上拍的照片
Related News
相关新闻
Can B Corp. Stock Takes A 51% Plunge On Record Quarterly Revenue
Can B Corp. 股价在创纪录的季度收入基础上暴跌了51％
译文内容由第三方软件翻译。